Search Results

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabin...

by Dena R Howard, Talha Munir, Lucy McParland, Andy C Rawstron, Anna Chalmers, Walter M Gregory, John L O’Dwyer, Alison Smith, Roberta Longo, Abraham Varghese, Alexandra Smith, Peter Hillmen
Published in Health Technology Assessment (2017)

Letter to the Editor: Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL, ARCTIC and ADMIRE clinical...

by Louise, Carr, Norris, Kevin, Helen, Parker, Anna, Nilsson-Takeuchi, Dean, Bryant, Harindra, Amarasinghe, Latha, Kadalayil, Monica, Else, Andrew, Pettitt, Peter, Hillmen, Anna, Schuh, Renata, Walewska, Baird, Duncan, G., Oscier David, C., Oakes Christopher, Jane, Gibson, Pepper, Christopher, C., Strefford Jonathan
Published in British Journal of Haematology (2024)

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials

by Tomasz K. Wojdacz, Harindra E. Amarasinghe, Latha Kadalayil, Alice Beattie, Jade Forster, Stuart J. Blakemore, Helen Parker, Dean Bryant, Marta Larrayoz, Ruth Clifford, Pauline Robbe, Zadie A. Davis, Monica Else, Dena R. Howard, Basile Stamatopoulos, Andrew J. Steele, Richard Rosenquist, Andrew Collins, Andrew R. Pettitt, Peter Hillmen, Christoph Plass, Anna Schuh, Daniel Catovsky, David G. Oscier, Matthew J.J. Rose-Zerilli, Christopher C. Oakes, Jonathan C. Strefford
Published in Blood Advances (2019)